$275.83
0.41% yesterday
NYSE, Sep 18, 10:13 pm CET
ISIN
US0311621009
Symbol
AMGN

Amgen Stock price

$275.83
-16.79 5.74% 1M
-42.82 13.44% 6M
+15.19 5.83% YTD
-57.09 17.15% 1Y
+45.07 19.53% 3Y
+28.11 11.35% 5Y
+125.24 83.17% 10Y
+189.66 220.10% 20Y
NYSE, Closing price Thu, Sep 18 2025
+1.12 0.41%
ISIN
US0311621009
Symbol
AMGN
Industry

Key metrics

Basic
Market capitalization
$148.5b
Enterprise Value
$196.7b
Net debt
$48.2b
Cash
$8.0b
Shares outstanding
538.0m
Valuation (TTM | estimate)
P/E
22.6 | 12.8
P/S
4.3 | 4.1
EV/Sales
5.6 | 5.4
EV/FCF
16.4
P/B
20.0
Dividends
DPS
$9.00
Yield 1Y | 5Y
3.3% | 3.1%
Growth 1Y | 5Y
5.6% | 9.2%
Payout 1Y | 3Y
119.1% | 78.6%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$34.9b | $36.4b
EBITDA
- | $20.8b
EBIT
$10.9b | $16.0b
Net Income
$6.6b | $11.6b
Free Cash Flow
$12.0b
Growth (TTM | estimate)
Revenue
12.9% | 8.9%
EBITDA
- | 36.7%
EBIT
75.2% | 66.0%
Net Income
111.5% | 183.1%
Free Cash Flow
119.2%
Margin (TTM | estimate)
Gross
69.7%
EBITDA
- | 57.3%
EBIT
31.3%
Net
19.0% | 31.8%
Free Cash Flow
34.4%
Financial Health
Equity Ratio
6.4%
Return on Equity
69.6%
ROCE
16.2%
ROIC
-
Debt/Equity
7.6
More
EPS
$12.2
FCF per Share
$22.3
Short interest
2.2%
Employees
28k
Rev per Employee
$1.2m
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

40 Analysts have issued a Amgen forecast:

21x Buy
53%
16x Hold
40%
3x Sell
8%

Analyst Opinions

40 Analysts have issued a Amgen forecast:

Buy
53%
Hold
40%
Sell
8%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
34,917 34,917
13% 13%
100%
- Direct Costs 10,578 10,578
7% 7%
30%
24,339 24,339
24% 24%
70%
- Selling and Administrative Expenses 6,840 6,840
5% 5%
20%
- Research and Development Expense 6,345 6,345
18% 18%
18%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 10,928 10,928
75% 75%
31%
Net Profit 6,619 6,619
111% 111%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Positive
Seeking Alpha
5 days ago
Amgen offers a compelling value and income opportunity after a recent price dip, trading below historical valuation multiples. AMGN posted strong Q2 results with robust performance across its innovative biologics and biosimilars portfolio. AMGN is well positioned for long-term growth, supported by a strong pipeline, demographic tailwinds, and a solid balance sheet with a 3.4% dividend yield.
Positive
The Motley Fool
5 days ago
Between labor-market data and potential interest-rate cuts, Wall Street has a lot on its plate right now. In an environment like this one, it can be helpful to invest in solid, dividend-paying stocks -- and due to its non-cyclical nature, the healthcare sector is a good place to find some.
Negative
Reuters
10 days ago
The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply with regulations that are already on the books, senior administration officials said on Tuesday.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today